ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
With just $100k supplementing a bootstrapped beginning, the Philly-founded edtech startup has expanded globally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback